Journal
AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS
Volume 25, Issue 2, Pages 119-124Publisher
SAGE PUBLICATIONS INC
DOI: 10.1177/1533317509350298
Keywords
Alzheimer's disease assessment scale; ADAS-Cog; item analysis; randomized controlled clinical trial; placebo
Categories
Funding
- Merck Research Laboratories
Ask authors/readers for more resources
We explored the association of Alzheimer's disease (AD) Assessment Scale (ADAS-Cog) item scores with AD severity using cross-sectional and longitudinal data from the same study. Post hoc analyses were performed using placebo data from a 12-month trial of patients with mild-to-moderate AD (N = 281 randomized, N = 209 completed). Baseline distributions of ADAS-Cog item scores by Mini-Mental State Examination (MMSE) score and Clinical Dementia Rating (CDR) sum of boxes score (measures of dementia severity) were estimated using local and nonparametric regressions. Mixed-effect models were used to characterize ADAS-Cog item score changes over time by dementia severity (MMSE: mild = 21-26, moderate = 14-20; global CDR: mild = 0.5-1, moderate = 2). In the cross-sectional analysis of baseline ADAS-Cog item scores, orientation was the most sensitive item to differentiate patients across levels of cognitive impairment. Several items showed a ceiling effect, particularly in milder AD. In the longitudinal analysis of change scores over 12 months, orientation was the only item with noticeable decline (8%-10%) in mild AD. Most items showed modest declines (5%-20%) in moderate AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available